"KAI generates drug candidates for kidney disease and leverages them into non-dilutive alliances, allowing us to overcome clinical and market risk. The path requires flexibility, vision, and perseverance, and InterWest bring these qualities to every challenging decision."
LeadershipSteve James, President and CEO
KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. KAI was acquired by Amgen in 2012.